Contemporary Drug Problems
August 11, 2026
Alana Roy, M.l. Williams, Kimberley Day et al.
Alternative healthcare practices using psychedelic “plant medicines,” such as ayahuasca, challenge current prohibition and mainstream healthcare frameworks. Despite the criminalization of ayahuasca's active component, N,N-dimethyltryptamine (DMT), Australian ayahuasca dietero networks have developed sophisticated healthcare systems with systematic assessment processes, safety mechanisms, and...
Frontiers in Neuroscience
January 31, 2023
Daniel Perkins, Kimberley Day, Jerome Sarris et al.
27 citations
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine (Spruce ex Griseb. Morton, Malpighiaceae), which contains three primary harmala alkaloids, along with the leaves of Psychotria viridis (Ruiz et Pavon, Rubiaceae) in which the potent psychedelic dimethyltryptamine (DMT) is found. DMT-harmaloid concoctions have gained popularity in recent...
February 14, 2022
Daniel Perkins, Simon Ruffell, Kimberley Day et al.
1 citation
preprint
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine, which contains three primary harmala alkaloids, along with the leaves of Psychotria viridis in which the potent psychedelic dimethyltryptamine (DMT) is found. DMT-harmaloid concoctions have gained popularity in recent years, due to growing anecdotal and scientific reports of therapeutic...
Current Opinion in Psychiatry
November 15, 2021
Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al.
12 citations
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent findings Serotonergic psychedelics have been found to modulate brain networks underlying various...